Hikma Pharmaceuticals (LON:HIK) was downgraded by analysts at Jefferies Group to an “underperform” rating in a research note issued on Wednesday. They currently have a GBX 895 ($12.14) price target on the stock, down from their previous price target of GBX 1,074 ($14.56). Jefferies Group’s target price points to a potential downside of 11.69% from the company’s previous close.

HIK has been the topic of several other reports. Stifel Nicolaus decreased their price target on shares of Hikma Pharmaceuticals from GBX 1,320 ($17.90) to GBX 1,000 ($13.56) and set a “hold” rating on the stock in a research note on Thursday, November 9th. Numis Securities upgraded shares of Hikma Pharmaceuticals to a “buy” rating and set a GBX 1,300 ($17.63) price objective on the stock in a report on Thursday, November 9th. Peel Hunt reiterated a “hold” rating and set a GBX 1,390 ($18.85) price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, October 31st. JPMorgan Chase & Co. cut their price objective on shares of Hikma Pharmaceuticals from GBX 1,500 ($20.34) to GBX 1,250 ($16.95) and set a “neutral” rating on the stock in a report on Friday, October 6th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a GBX 1,100 ($14.92) price objective on shares of Hikma Pharmaceuticals in a report on Friday, December 1st. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of GBX 1,171 ($15.88).

Hikma Pharmaceuticals (LON:HIK) traded down GBX 4 ($0.05) during trading on Wednesday, hitting GBX 1,013.50 ($13.74). 427,162 shares of the company’s stock traded hands, compared to its average volume of 720,152. Hikma Pharmaceuticals has a one year low of GBX 906.50 ($12.29) and a one year high of GBX 2,346 ($31.81). The firm has a market cap of $2,410.00 and a PE ratio of 2,027.00.

TRADEMARK VIOLATION NOTICE: “Hikma Pharmaceuticals (HIK) Stock Rating Lowered by Jefferies Group” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/hikma-pharmaceuticals-hik-stock-rating-lowered-by-jefferies-group/1807215.html.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.

Analyst Recommendations for Hikma Pharmaceuticals (LON:HIK)

Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.